Scarica l'app Stockscreener
22.54
2.47%
-0.57
Dopo l'orario di chiusura:
22.18
-0.36
-1.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$23.11
Aprire:
$22.94
Volume 24 ore:
3.71M
Relative Volume:
1.89
Capitalizzazione di mercato:
$2.17B
Reddito:
$610.16M
Utile/perdita netta:
$-532.93M
Rapporto P/E:
-4.0769
EPS:
-5.5287
Flusso di cassa netto:
$-442.30M
1 W Prestazione:
-1.05%
1M Prestazione:
-38.04%
6M Prestazione:
-43.52%
1 anno Prestazione:
-47.16%
Intervallo 1D:
$22.07
$23.16
Intervallo di 1 settimana:
$21.90
$24.00
Portata 52W:
$18.41
$46.50
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
22.54 | 2.23B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx ... - Bluefield Daily Telegraph
Ultragenyx Pharma stock price target lowered to $60 at H.C. Wainwright - Investing.com
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401 - CGTLive®
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ultragenyx Pharmaceutical (RARE) Target Price Lowered by HC Wain - GuruFocus
HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $60.00 - MarketBeat
Guggenheim lowers Ultragenyx Pharma stock price target on trial failures By Investing.com - Investing.com Nigeria
2026-01-05 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Ultragenyx Pharmaceutical (RARE): Guggenheim Lowers Price Target - GuruFocus
Guggenheim lowers Ultragenyx Pharma stock price target on trial failures - Investing.com
Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (RARE) Advances Gene Therapies, But How Durable Is Its Rare-Disease Strategy? - Yahoo Finance
Ultragenyx completes rolling FDA submission for US approval of gene therapy - MSN
StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide - Benzinga
ATTENTION Ultragenyx Pharmaceutical Inc. (RARE) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ultragenyx stock eyes best day in 17 months as Wall Street shifts focus to 2026 pipeline after bone disease trial miss - MSN
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE) - ACCESS Newswire
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease - BioPharm International
Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Pharmaceutical (RARE): B of A Securities Lowers Price Target | RARE Stock News - GuruFocus
Ultragenyx completes rolling submission of BLA for DTX401 - The Pharma Letter
Ultragenyx Pharmaceuticals Loses $1 Billion in Market Value After Bone Drug Fails Phase III Trials - geneonline.com
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials By Investing.com - Investing.com South Africa
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures - BioSpace
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials - Investing.com
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials - Fierce Biotech
Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials - Indian Pharma Post
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy - The Globe and Mail
Lacklustre Performance Is Driving Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 32% Price Drop - 富途牛牛
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Levi & Korsinsky Launches Fraud Investigation on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Shareholders - ACCESS Newswire
Ultragenyx (RARE) Completes U.S. Application for Gene Therapy DT - GuruFocus
Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus - ts2.tech
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? - Yahoo Finance
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall - Finviz
Ultragenyx (RARE) rockets 15.5% on bargain-hunting after steep fall - MSN
Why Ultragenyx Pharmaceuticals stock is plummeting today - MSN
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Why Did RARE Stock Plunge Over 41% Today? - Stocktwits
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):